Cushman P, Sowers J R
Department of Medicine, Medical College of Virginia, Richmond.
Alcohol Clin Exp Res. 1989 Jun;13(3):361-4. doi: 10.1111/j.1530-0277.1989.tb00336.x.
Lofexidine (L) was compared to placebo (P) in a random double blind placebo controlled study of 23 healthy alcoholics in withdrawal. In serial alcohol withdrawal syndrome (AWS) scales, P greater than L for first 18 hr. The major changes in AWS were in blood pressure and pulse, while restlessness or diaphoresis did not show faster normalization with L vs. P. Other ratings of withdrawal intensities and craving by patients were similar in both P and L. There were no differences in the rate of patient completion, or appearance of hallucinations by group. Plasma catecholamines were in the high ranges, similar in both groups at 0 and 3 hr, but after 5 hr P greater than L for norepinephrine (but not epinephrine or dopamine). The data suggest L has pharmacological effects on some objective, catecholamine related, components of alcohol withdrawal, with little effect on others. L type treatment of alcoholics in withdrawal is promising, modestly effective and warrants further study.
在一项针对23名正在戒酒的健康酗酒者的随机双盲安慰剂对照研究中,将洛非西定(L)与安慰剂(P)进行了比较。在连续酒精戒断综合征(AWS)量表中,在前18小时内,P组大于L组。AWS的主要变化在于血压和脉搏,而L组与P组相比,躁动或发汗并没有更快恢复正常。患者对戒断强度和渴望的其他评分在P组和L组中相似。两组在患者完成率或幻觉出现方面没有差异。血浆儿茶酚胺处于较高水平,两组在0小时和3小时时相似,但在5小时后,去甲肾上腺素(而非肾上腺素或多巴胺)的水平P组大于L组。数据表明,L对酒精戒断的一些与儿茶酚胺相关的客观成分具有药理作用,而对其他成分影响较小。L型治疗戒酒者具有前景,有一定疗效,值得进一步研究。